| 1 |
34837846 | High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. | 2022 Jan |
1 |
| 2 |
30795621 | The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells. | 2019 Feb 21 |
2 |
| 3 |
28808038 | The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. | 2017 Nov 1 |
2 |
| 4 |
25855885 | Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. | 2015 Jun |
1 |
| 5 |
22801959 | Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. | 2013 Jan |
1 |
| 6 |
23053270 | PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. | 2013 Jan |
1 |
| 7 |
23602735 | Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. | 2013 Oct |
1 |
| 8 |
24004591 | [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line]. | 2013 May |
1 |
| 9 |
24218548 | Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. | 2013 Nov 26 |
1 |
| 10 |
22101421 | The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. | 2012 Feb |
1 |
| 11 |
22415236 | The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. | 2012 Apr 10 |
1 |
| 12 |
19509167 | Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. | 2009 Jun 15 |
1 |